These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32292094)

  • 21. Reducing the risk of obesity: defining the role of weight loss drugs.
    Ling H; Lenz TL; Burns TL; Hilleman DE
    Pharmacotherapy; 2013 Dec; 33(12):1308-21. PubMed ID: 23712541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacotherapy for obesity in individuals with type 2 diabetes.
    Chukir T; Shukla AP; Saunders KH; Aronne LJ
    Expert Opin Pharmacother; 2018 Feb; 19(3):223-231. PubMed ID: 29376439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological Treatment for Obesity in Adults: An Umbrella Review.
    Khalil H; Ellwood L; Lord H; Fernandez R
    Ann Pharmacother; 2020 Jul; 54(7):691-705. PubMed ID: 31958967
    [No Abstract]   [Full Text] [Related]  

  • 24. The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database.
    Gorelik E; Gorelik B; Masarwa R; Perlman A; Hirsh-Raccah B; Matok I
    Int J Obes (Lond); 2020 May; 44(5):1021-1027. PubMed ID: 32152496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Past and present of antiobesity agents: focus on monoamine modulators.
    Khorassani FE; Misher A; Garris S
    Am J Health Syst Pharm; 2015 May; 72(9):697-706. PubMed ID: 25873617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Comparison of New Pharmacological Agents for the Treatment of Obesity.
    Nuffer W; Trujillo JM; Megyeri J
    Ann Pharmacother; 2016 May; 50(5):376-88. PubMed ID: 26887340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The risk of cardiovascular complications with current obesity drugs.
    Chao AM; Wadden TA; Berkowitz RI; Quigley K; Silvestry F
    Expert Opin Drug Saf; 2020 Sep; 19(9):1095-1104. PubMed ID: 32750250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination phentermine and topiramate extended release in the management of obesity.
    Alfaris N; Minnick AM; Hopkins CM; Berkowitz RI; Wadden TA
    Expert Opin Pharmacother; 2015 Jun; 16(8):1263-74. PubMed ID: 25958964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term drug treatment for obesity: a systematic and clinical review.
    Yanovski SZ; Yanovski JA
    JAMA; 2014 Jan; 311(1):74-86. PubMed ID: 24231879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug treatment of obesity: current status and future prospects.
    Kakkar AK; Dahiya N
    Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of Antiobesity Treatment and Weight-Inducing Antihyperglycemic Agents Among Patients With Type 2 Diabetes in the United States.
    Levin A; Kaur N; Mainoo NK; Perez A
    Clin Ther; 2022 Mar; 44(3):e35-e44. PubMed ID: 35105470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
    Kelly EM; Tungol AA; Wesolowicz LA
    J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Past, present and future of pharmacotherapy for obesity.
    Benaiges D; Pedro-Botet J; Flores-Le Roux JA; Climent E; Goday A
    Clin Investig Arterioscler; 2017; 29(6):256-264. PubMed ID: 28935287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Obesity medications: what does the future look like?
    Butsch WS
    Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):360-6. PubMed ID: 26313898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Drug treatment of obesity--current situation and perspectives].
    Hainer V
    Cas Lek Cesk; 2010; 149(11):513-9. PubMed ID: 21391349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
    Shi Q; Wang Y; Hao Q; Vandvik PO; Guyatt G; Li J; Chen Z; Xu S; Shen Y; Ge L; Sun F; Li L; Yu J; Nong K; Zou X; Zhu S; Wang C; Zhang S; Qiao Z; Jian Z; Li Y; Zhang X; Chen K; Qu F; Wu Y; He Y; Tian H; Li S
    Lancet; 2022 Jan; 399(10321):259-269. PubMed ID: 34895470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New treatment modalities for obesity.
    Grandone A; Di Sessa A; Umano GR; Toraldo R; Miraglia Del Giudice E
    Best Pract Res Clin Endocrinol Metab; 2018 Aug; 32(4):535-549. PubMed ID: 30086873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
    Kiortsis DN
    Hormones (Athens); 2013; 12(4):507-16. PubMed ID: 24457398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
    Fujioka K; Braverman-Panza J
    J Fam Pract; 2016 Jul; 65(7 Suppl):S16-23. PubMed ID: 27565106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.